Read + Share
Oyama K, Raz I, Cahn A, Kuder J, et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in
patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J 2022;43:2958-2967.
PMID: 34427295
|
 |
|
Oyama K, Raz I, Cahn A, Kuder J, et al. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in
patients with type 2 diabetes mellitus in the DECLARE-TIMI 58 trial. Eur Heart J 2022;43:2958-2967.
PMID: 34427295
|
|
|
|